Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CSL112 after acute myocardial infarction
MOH_2018-05-24_002401Phase 3Not yet recruiting
- Sponsor
- CSL Limited
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and myocardial infarction (MI) comparing CSL112 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start May 2018; status: not yet recruiting.
02
Drugs
CSL112
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2018-05-24_002401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-24_002401.